FDA approves Horizant for PHN

FDA approved Horizant gabapentin enacarbil from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to manage postherpetic neuralgia. Horizant is already marketed in the U.S. to treat restless legs syndrome (RLS). GSK plans to launch the product for PHN in mid-July. The wholesale acquisition cost (WAC) is $3.50 per 600 mg tablet, with a recommended PHN dose of 600 mg twice daily. GSK has U.S. commercialization rights from XenoPort Inc. (NASDAQ:XNPT), which is eligible for a $10 million milestone payment upon GSK's first sale of Horizant for PHN. XenoPort was down $0.58 (10%) to $5.49 on Thursday. ...